Failure of GPI compounds to display neurotrophic activity in vitro and in vivo.
The aim of this study was to evaluate the neurotrophic and neuroprotective properties of a series of immunophilin ligands and to assess the potential involvement of FK506 Binding Protein 12 kDa (FKBP12) rotamase inhibition in this activity. Both FK506 and rapamycin induced a potent inhibition of the FKBP12 rotamase activity (pIC(50) values of 7.3 and 7.4, respectively) but only a modest inhibition was observed with 1-(3,3-dimethyl-2-oxo-pentanoyl)-pyrrolidine-2-carboxylic acid S-3-pyridin-3-yl-propyl ester (GPI 1046) (5.8), its N-oxide (5.4) and thioester (6.3) analogues. Compared to nerve growth factor, all these immunophilin ligands only induced marginal increases in neurite outgrowth of rat dissociated newborn dorsal root ganglia cells. Furthermore, systemic administration of GPI 1046 and its N-oxide and thioester analogues failed to prevent striatal dopamine depletion induced by acute or chronic i.p. treatment with 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP). These results suggest that inhibition of FKBP12 rotamase activity is not predictive for neurotrophic and neuroprotective properties of immunophilin ligands and question their therapeutic utility in neurodegenerative diseases like Parkinson's disease.
Preclinical CNS Research, UCB S.A. Pharma Sector, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.
A
A
Bocquet
G
G
Lorent
B
B
Fuks
R
R
Grimée
P
P
Talaga
J
J
Daliers
H
H
Klitgaard
D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D005727:Ganglia, Spinal / Q000187:drug effects* / Q000502:physiology; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008024:Ligands; D020267:MPTP Poisoning / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D020123:Sirolimus / Q000494:pharmacology; D022021:Tacrolimus Binding Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism
C104949:GPI 1046; D007166:Immunosuppressive Agents; D008024:Ligands; D018696:Neuroprotective Agents; D011759:Pyrrolidines; D022021:Tacrolimus Binding Proteins; D004298:Dopamine; D020123:Sirolimus